With nine vaccines now showing they can powerfully prevent severe illness and death from #COVID19—and vaccines in short supply—researchers are mulling an issue that, even a few months ago, was only hypothetical: Should people mix and match vaccines that require two shots?
Scarce vaccine supplies ramp up interest in combining different doses.
An Israeli drug that has been successful in initial trials, could hold a key in blunting the COVID-19 pandemic. Thirty patients in serious condition participated in the trial and all recovered, most of them in less than a week. Sonya Cohen was one of them and she could one day be seen as a walking #miracle.
Follow Jerusalem Dateline and download the CBN News app to ensure you keep receiving news from a Christian Perspective. go.cbn.com/cbnapp.
#covidcure #Israel #Israeli #innovation #fightcovid #breakthrough.
Ichilov Hospital, Tel Aviv
Elon Musk is serious about making the upcoming Tesla Roadster “hover” with rocket technology in new comments about the electric supercar.
When first unveiling the vehicle, Tesla claimed a list of impressive specs for its new Roadster, including 0–60 mph in 1.9 sec, 620-mile of range, and more.
The CEO has been also teasing those specs as the “base specs,” and other versions should have even crazier performance.
Tesla CEO Elon Musk gave some details about the prospective electric van that the company could develop in the coming years. In an interview with Joe Rogan on the comedian’s podcast, the Joe Rogan Experience, Musk indicated that a van’s design would be more favorable to equip solar panels for stationary charging.
During Tesla’s Q4 2020 Earnings Call, TBC Capital Markets analyst Joseph Spak asked Musk about the possibility of developing an all-electric van. Vans have become a major player in the EV space since Rivian was contracted by e-commerce giant Amazon to build 100000 electric delivery vans. The vans have recently started testing in Southern California. Ford also developed an electric version of its Transit van.
The prospect of Tesla developing an electric van was confirmed by Musk during the Earnings Call.
Many researchers are already working on developing vaccines for the next pandemic, even though they don’t know what it will be. (Craig Chivers/CBC.
When the next coronavirus pandemic hits, scientists plan to already have a vaccine against it, no matter what it is. But how is that possible? Here’s what they’re doing now to develop vaccines against emerging viruses and future variants of COVID-19.
Popular energy drinks may give you a boost, but they may also contribute to possible serious heart conditions, findings show.
A team of researchers, led by a Texas A&M University professor, has found that some energy drinks have adverse effects on the muscle cells of the heart.
The study, led by Dr. Ivan Rusyn, a professor in the Veterinary Integrative Biosciences (VIBS) Department at the Texas A&M College of Veterinary Medicine & Biomedical Sciences (CVMBS), was published in Food and Chemical Toxicology. In it, researchers observed cardiomyocytes – human heart cells grown in a laboratory – exposed to some energy drinks showed an increased beat rate and other factors affecting cardiac function.
More Space news.
The Chinese Tianwen-1 mission to Mars successfully entered Mars orbit on February 102021, only one day after the United Arab Emirates mission Hope arrived at the red planet on February 9. They’ll be followed soon by NASA’s Perseverance mission which is set to arrive and land on February 18.
57:03 “A tool that would be used for millenia.”
Foresight biotech & health extension group sponsored by 100 plus capital.
Accelerator applications are open now: https://foresight.org/biotech-health-extension-program.
Industry blindspots: Unincentivized work that could dramatically advance progress on aging.
SONIA ARRISON, 100 Plus Capital.
Sonia Arrison is a best-selling author, analyst, entrepreneur, and investor. She is the founder of 100 Plus Capital, co-founder of Unsugarcoat Media (acquired by Medium), and associate founder and advisor to Singularity University in Mountain View, California. Her research focuses on exponentially growing technologies and their impact on society. Her most recent book, 100 Plus: How the Coming Guests Age of Longevity Will Change Everything, From Careers and Relationships to Family and Faith, addresses the social, economic, and cultural impacts of radical human longevity. It gained national bestseller status and keeps Sonia busy speaking all over the world. Sonia is a Board Member at the Thiel Foundation, Foresight Institute, and Woodland School. She is also a Senior Fellow at the Fraser Institute in Vancouver, British Columbia, and author of two previous books (Western Visions and Digital Dialog). She was previously a Director and Senior Fellow in Tech Studies at the Pacific Research Institute and a columnist at TechNewsWorld.
KARL PFLEGER, Agingbiotech.info.
Karl Pfleger, PhD (Stanford CS, Machine Learning) now focuses on aging & longevity after a successful tech career (mySimon, Google). A long-time donor to the Buck Institute and SENS Foundation, he is also an angel investor who has backed over 15 agingrelated startups. He is the creator of AgingBiotech. info, a free public resource to track the commercialization progress of the aging biotech sector and related information.
MIKE WEST, AgeX
Michael D. West, Ph.D., is the founder and CEO of AgeX Therapeutics, Inc, which is focused on the development and commercialization of novel therapeutics targeting human aging. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular ageing. He has focused his academic and business career on the application of developmental biology to agerelated degenerative disease. He was the founder and first CEO of Geron Corporation (Nasdaq: GERN), and from 1992 to 1998, he held various positions, including CEO, Director, and Vice President. From 1998 to 2007, Dr West held positions as CEO, President, and Chief Scientific Officer at Advanced Cell Technology, Inc. (ACT), which was eventually acquired by Astellas Pharma, Inc. From 2007 to 2018, he was CEO/Co-CEO of BioTime, Inc. (NYSE American: BTX).
Zoom Transcription:
https://otter.ai/u/kGO_zgxGxUbbd63_6wfM0x_RQsA
The toolset runs with Q-CTRL’s flagship BOULDER OPAL software for developers and R&D teams, automated closed-loop hardware optimization is also trained to obtain new experimental data/results from quantum computers while simultaneously running optimizations for algorithms. It can be used as a standalone tool or in tandem with a machine-learner online optimization package (M-LOOP) that manages quantum experiments autonomously.
To build a universal quantum computer from fragile quantum components, effective implementation of quantum error correction (QEC) is an essential requirement and a central challenge. QEC is used in quantum computing, which has the potential to solve scientific problems beyond the scope of supercomputers, to protect quantum information from errors due to various noise.